Cardiac Safety Could Be Distinguishing Point For Sunovion's New Antipsychotic Latuda
Lack of a cardiac safety signal looks to be a key selling point for Sunovion Pharmaceuticals' atypical antipsychotic Latuda (lurasidone).
You may also be interested in...
TOKYO - Dainippon Sumitomo launched its atypical antipsychotic Latuda (lurasidone) in the U.S. Feb. 4, and now the pressure is on to capitalize on the sales force it acquired in the acquisition of Sepracor. Analysts' eyes will be on Latuda's initial sales to gauge the company's acquired ability to market its in-house drugs in the U.S
Company will use newly acquired Sepracor sales force for the atypical antipsychotic.
Buying the Lunesta marketer gives the Japanese pharma an experienced U.S. regulatory and commercial team ahead of lurasidone launch.